Since MED1 phosphorylation is significantly increased during prostate cancer progression (Figure 7A), we proposed that pharmacological inhibition of CDK9 can block MED1 phosphorylation, transcription recycling and CRPC growth. This evidence concerns the gene MED1 and prostate carcinoma.